Literature DB >> 3671242

Amyloid myopathy and myeloma: response to treatment.

R A Sheehan-Dare1, A V Simmons.   

Abstract

A 57 year old female presented with an amyloid myopathy in association with lambda light chain myeloma. Treatment with melphalan and prednisolone resulted in remission of both myeloma and myopathy.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3671242      PMCID： PMC2428236          DOI： 10.1136/pgmj.63.736.141

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  8 in total

1.  Amyloidosis of the AL type. Clinical, morphologic and biochemical aspects of the response to therapy with alkylating agents and prednisone.

Authors:  J N Buxbaum; M E Hurley; J Chuba; T Spiro
Journal:  Am J Med       Date:  1979-11       Impact factor: 4.965

2.  Resolution of primary amyloidosis during chemotherapy. Studies in a patient with nephrotic syndrome.

Authors:  H J Cohen; L S Lessin; J Hallal; P Burkholder
Journal:  Ann Intern Med       Date:  1975-04       Impact factor: 25.391

3.  Resolution of renal amyloidosis.

Authors:  S H Dikman; T Kahn; D Gribetz; J Churg
Journal:  Am J Med       Date:  1977-09       Impact factor: 4.965

4.  Treatment of "primary" renal amyloidosis with melphalan.

Authors:  N F Jones; P J Hilton; J R Tighe; J R Hobbs
Journal:  Lancet       Date:  1972-09-23       Impact factor: 79.321

5.  Regression of amyloidosis in multiple myeloma.

Authors:  A D Mehta
Journal:  Br J Clin Pract       Date:  1978-12

6.  Therapy of primary amyloidosis with melphalan and prednisone.

Authors:  R S Schwartz; J R Cohen; S L Schrier
Journal:  Arch Intern Med       Date:  1979-10

7.  Primary systemic amyloidosis: resolution of the nephrotic syndrome with melphalan and prednisone.

Authors:  R A Kyle; R D Wagoner; K E Holley
Journal:  Arch Intern Med       Date:  1982-08

Review 8.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616
  8 in total
  1 in total

1.  Myopathy in primary systemic amyloidosis.

Authors:  M A Gertz; R A Kyle
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.